PT  - JOURNAL ARTICLE
AU  - AOYAMA, TORU
AU  - KATO, AYA
AU  - HASHIMOTO, ITARU
AU  - MAEZAWA, YUKIO
AU  - HARA, KENTARO
AU  - KAWAHARA, SHINNOSUKE
AU  - KAZAMA, KEISUKE
AU  - KOMORI, KEISUKE
AU  - YOSHIZAWA, SUZUE
AU  - TAMAGAWA, AYAKO
AU  - TATEISHI, MINORI
AU  - MINAMI, TOMOYUKI
AU  - CHO, HARUHIKO
AU  - MORITA, JUNYA
AU  - OTANI, KAZUKI
AU  - SAWAZAKI, SHO
AU  - NUMATA, MASAKATAU
AU  - TANABE, MIE
AU  - OSHIMA, TAKASHI
AU  - SAITO, AYA
AU  - YUKAWA, NORIO
AU  - RINO, YASUSHI
TI  - Pretreatment Fibrinogen Level Is a Prognostic Factor for Esophageal Cancer Patients Who Receive Curative Treatment
AID  - 10.21873/anticanres.16808
DP  - 2024 Jan 01
TA  - Anticancer Research
PG  - 249--255
VI  - 44
IP  - 1
4099  - http://ar.iiarjournals.org/content/44/1/249.short
4100  - http://ar.iiarjournals.org/content/44/1/249.full
SO  - Anticancer Res2024 Jan 01; 44
AB  - Background/Aim: Pretreatment fibrinogen levels are a promising prognostic marker for some malignancies. The aim of the present study was to evaluate the clinical impact of fibrinogen levels before treatment in patients with esophageal cancer who underwent curative resection. Patients and Methods: This study included 123 patients who underwent curative treatment for esophageal cancer between 2005 and 2020. The prognosis and clinicopathological parameters in the high fibrinogen and low fibrinogen groups were analyzed. Results: Overall survival (OS) stratified by individual clinical factors was compared using the log-rank test, and a significant difference was observed when a pretreatment fibrinogen level of 400 g/dl was used as a cutoff value. The comparison of the patient background factors between the high fibrinogen (400 g/dl) and low fibrinogen (<400 g/dl) groups revealed significant differences in pathological T status and lymph node metastasis. In the low fibrinogen group, the OS rates at 3 and 5 years after surgery (71.4% and 58.1%, respectively) were significantly higher than those in the high fibrinogen group (38.3% and 32.4%, respectively). Univariate and multivariate analyses for OS showed that the fibrinogen level prior to treatment was a significant prognostic factor. Similar results were observed for recurrence-free survival. In addition, when the first recurrence site was compared, there were marginally significant differences in hematologic recurrence. Conclusion: Pretreatment fibrinogen levels are a significant risk factor in patients with esophageal cancer. Therefore, pretreatment fibrinogen levels are a promising prognostic factor for patients with esophageal cancer.